Literature DB >> 8869477

Inhibitors to coagulation: can we afford immune tolerance induction regimens?

L M Aledort1.   

Abstract

Mesh：

Substances：

Year:  1996        PMID： 8869477

Source DB:  PubMed          Journal:  Vox Sang        ISSN： 0042-9007            Impact factor:   2.144


× No keyword cloud information.
  2 in total

1.  Cost-utility analysis of factor VIII diet therapies prepared using blood plasma vs. recombinant technique for patients with hemophilia A.

Authors:  Farhad Lotfi; Hamid Talebianpour; Khosro Keshavarz; Fatemeh Emadi; Mohammad Reza Bordbar; Peivand Bastani
Journal:  Daru       Date:  2020-04-22       Impact factor: 3.117

2.  Cost-utility analysis of immune tolerance induction therapy versus on-demand treatment with recombinant factor VII for hemophilia A with high titer inhibitors in Iran.

Authors:  Hamid Reza Rasekh; Ali Imani; Mehran Karimi; Mina Golestani
Journal:  Clinicoecon Outcomes Res       Date:  2011-11-23
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.